RxDoctor Payments Data

Enrique Maldonado Corchado, MD

Endocrinology, Diabetes & Metabolism · Guaynabo, PRNPI 1972873792

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,809 of the $8,235 with a category attached, or 82.7%. It is spread thinly across 29 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,775 and has fallen 79.1% since, to $579 in 2025.

$8,235in general payments, 2019–2025

Across 367 payments — averaging $22.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$2K
  • Novo Nordisk$1K
  • Amgen$808
  • Bayer Puerto Rico Inc.$679
  • Abbott$579
  • AstraZeneca$544
  • plus $3K from 23 others

What the payments were for

  • Speaking & faculty fees$1,40017%
  • Food & beverage$6,80983%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,235 in reported general payments places this provider in the 70th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

See all endocrinology, diabetes & metabolism providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$11,152
Medicare patients
47
Services billed
112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KorlymMifepristone13$516,798
OzempicSemaglutide482$487,906
Synjardy XrEmpagliflozin/Metformin Hcl392$300,649
MounjaroTirzepatide229$255,951
Trijardy XrEmpaglifloz/Linaglip/Metformin264$198,378
TrulicityDulaglutide188$193,351
JardianceEmpagliflozin166$111,114
GlyxambiEmpagliflozin/Linagliptin141$101,598
Xigduo XrDapaglifloz Propaned/Metformin161$96,939
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog135$95,776
FarxigaDapagliflozin Propanediol124$83,519
SynthroidLevothyroxine Sodium993$73,149
RybelsusSemaglutide60$71,977
Humalog Kwikpen U-200Insulin Lispro42$65,910
Janumet XrSitagliptin Phos/Metformin Hcl94$60,686

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimSynjardy Xr, Trijardy Xr, Jardiance, Glyxambi, Jentadueto Xr$281$759,8381,044 claims
Novo NordiskOzempic, Rybelsus$1,265$559,883542 claims
Corcept TherapeuticsKorlym$1,722$516,79813 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi, Humulin 70-30$185$497,529671 claims
MerckJanumet Xr, Januvia, Janumet$442$99,553154 claims
AstraZenecaFarxiga$544$83,519124 claims
AbbVieSynthroid$201$73,149993 claims
Sanofi-aventis U.S. LLCLantus, Soliqua 100-33$145$49,097404 claims
BayerKerendia$154$30,48938 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

Other endocrinology, diabetes & metabolism in Guaynabo

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →